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Research Paper
New Symmetrical Quinazoline Derivatives Selectively Induce Apoptosis
in Human Cancer Cells
ABSTRACT
In the search of new symmetrical derivatives with anticancer activity, we have looked
for novel compounds able to induce a selective proapoptotic mechanism in cancer cells.
The potential antitumoral activity of several quinazoline derivatives was evaluated in
vitro examining their cytotoxic effects against human breast, colon and bladder cancer
cell lines. The IC50 value of the compounds that showed cytotoxic activity was calculated.
These compounds were tested for their ability to induce caspase-3 activation and nuclear
chromatin degradation.
Non-tumoral human cell lines were used to test the selectivity of the cytotoxic compounds
against cancer cells. Several compounds showed no cytotoxicity in these cell lines.
Finally, JRF12 (2,4-dibenzylaminoquinazoline) was chosen as the best candidate and
its mechanism of action was studied in more detail. A time dependent evaluation of
apoptosis was performed in the three cancer cell lines, followed by an evaluation of the
cell cycle regulation involvement that showed a decrease of cells in G1 phase and increase
of cells in G2 phase before cell death.
2,4-dibenzylaminoquinazoline treatment produces few changes in the expression of
genes as evaluated by using oligonucleotide microarrays and Q-RT-PCR assays.
In conclusion, 2,4-dibenzylaminoquinazoline is a promising anticancer drug showing
cytostatic and apoptotic effects mainly in a transcription independent manner.
INTRODUCTION
Apoptosis is a highly regulated process important in embryonic and immune system
development and tissue homeostasis.1-4 This process is characterized by specific morphologic
changes such as cell size compaction, chromatin condensation, DNA degradation, membrane
blebbing and cell fragmentation into apoptotic bodies. The principal biochemical effectors
of apoptosis are the caspases, that are synthetized as inactive zymogens that once activated
cause the degradation of a variety of intracellular substrates and produce cell death.5-10
It is accepted that tumor growth may principally be due to reduced rates of cell death
rather than to enhanced proliferation.11-13 The process of apoptosis is now recognized as
an important component of multi step carcinogenesis.3,14-18 However, most cancer
chemotherapy regimens make use of highly cytotoxic drugs that target proliferating cell
populations. The non-discriminatory nature of these agents leads to severe side effects in
normal cells with a high proliferative index, such as those of the gastrointestinal tract and
bone marrow, thus limiting the effective dose of anticancer drug that can be administered.19
In the search of less toxic anticancer therapies, we have looked for novel compounds
with anticancer activity based on a proapoptotic mechanism. In the design of these new
structures, a general pattern has been adopted. These molecules have a central nucleus
made up of an aromatic system, the ring of quinazoline, connected to two identical lateral
arms consisting of an amine aliphatic chain of variable length and flexibility with or without
heterocycles at the end of the chain.
Recently, we have described the synthesis of symmetrical derivatives as cytotoxic and
apoptosis inducers.20,21 In our search for new molecules with these activities, we have
synthesized new derivatives of quinazoline 2,4-difunctionalized (unpublished results).
The central nucleus of quinazoline is involved in numerous biological activities, mainly
in cancer, as the inhibition of folate metabolism and the inhibition of the tyrosine kinase
activity, apoptosis induction and topoisomerase inhibition.22-36
The cytotoxicity of thirteen derivatives of quinazoline was evaluated. After confirmation
of their implication in apoptosis and their lack of toxicity against non-tumoral human cell
lines, 2,4-dibenzylaminoquinazoline (referred as JRF12) was chosen for the further study
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of its mechanism of action because of its suitable apoptotic and cyto-
toxic profile.
MATERIAL AND METHODS
Cell lines and reagents. The five human cell lines were obtained
from the American Tissue Culture Collection (Manassas, VA):
HT29 (ATCC HTB 38) is a colon adenocarcinoma cell line, T24
(ATCC HTB-24) was obtained from urinary bladder cancer,
MDA-MB-231 (ATCC HTB26) was established from adenocarci-
noma of mammary gland , CRL8799 was obtained from breast
epithelium (ATCC 184B5) and CRL11233 (ATCC THLE-3) from
human liver.
HT29 and T24 cells were cultured in McCoys medium (Gibco),
MDA-MB-231 in Leibovitz (Gibco), CRL8799 in MEG (Clonetics
Corporation) and CRL11233 in BEGM (BEGM Bullet kit,
Clonetics Corporation). These media were supplemented with 10%
fetal bovine serum, penicillin (50 U/ml) and streptomycin (50 µg/mL).
Cells were grown as monolayer in 175 cc flasks (Corning) and were
incubated at 37˚C in a humidified atmosphere containing 5% CO2.
The evaluated compounds were dissolved in dimethyl sulfoxide
(DMSO). The DMSO concentration was equalized in all media. In
all cases, the concentration of solvent in culture medium did not
exceed 0.5% (v/v).
Cytotoxicity study. Cytotoxicity was determined by using the
neutral red assay as described by Lowik et Albas.37 Ninety-six well
flat bottom tissue culture plates (Microtest 96 Falcon, Becton
Dickinson) were used for the experiments. Cells were resuspended
in culture medium and 180 µL of cell suspension were added into
each well. Cells were seeded at a density of 20 x 103/well, and then
cultured for 14 h to assure similar attachment of all cells. Test agents
or vehicle were then added to the cells in 20 µL of culture medium
and incubated for 72 h. After washing with PBS, the cells were
incubated at 37˚C with neutral red during 1. 5 h. The dye was then
extracted from the cells by the addition of 100 µL 0.05 M
NaH2PO4 in 50% ethanol. Optical density was measured at 540 nm
and 650 nm was used as a reference wavelength using a microtiter
plate reader (Organon tecknica). The spectrophotometer was
blanked on the first column of control wells containing solvent
solution alone.38,39
Survival percentage was determined at the screening concentrations
of 20 and 100 µM, using the survival percentage obtained with the
cells treated only with the solvent (DMSO at 0.5%) as reference.
The results are expressed as the average of triplicate assays. IC50
values were calculated for those compounds showing less than 50%
survival in the cell lines at 100 µM concentration. This value was
determined in triplicate by curvilinear regression analysis using the
statistical program SPSS 11.0.
With regard to selectivity, cytotoxicity was determined in cell
cultures of two non-tumoral lines, CRL-7899 and CRL-11233. The
highest IC50 calculated in the three tumoral lines was selected as the
test concentration for assays on non-tumoral cells. The IC50 obtained
in MDA-MB-231 was evaluated in breast non-tumoral cells.
Colony formation assay. The different cell lines were seeded in
six-well plates (Falcon, Becton Dickinson), cultured for 14 h and
treated for 24 h with vehicle or with the IC50 of JRF12. Cells were
then washed, fresh medium was added and incubation was continued
for 7 days.
Cells were fixed with 100% methanol for 2 minutes and then
stained with 1% toluidine blue. Colonies were counted and expressed
as the percent survival relative to non-treated cells. Cell viability is
expressed as medium ± SD of percent colonies formed 7 days after
treatment, referred to control cells. Each experiment was performed
by triplicate.
DNA fragmentation analysis. DNA fragmentation was measured
at 48 h after treatment using the Cell Death detection ELISAPLUS kit
(Roche Diagnostics, Indianapolis, IN) exactly as recommended by
manufacturer.40-42
In brief, the different cell lines were seeded in 96-well plates (2 x
104 cell/well). The cells were treated with various drugs at the IC50
for 48 h and then, after lysis in 200 µL lysis buffer for 30 min at
room temperature; the lisates were centrifuged at 200 g for 10 min
and after that, 20 µL from the supernatant were transferred to strep-
tavidin-coated microtitre plates for analysis. Eighty microliters of the
inmunoreagent containing monoclonal antibodies directed against
DNA and histones were added to each well, and the plates were
incubated on a shaker (300 r.p.m.) for 2 h at room temperature. The
solution was then removed and the wells were rinsed three times with
incubation buffer. One-hundred microliters of substrate solution
were added to each well and after 10–20 min, the amount of citosolic
mono- and oligonucleosomes (indicator of cell death) was determined
spectrophotometrically at 405 nm using substrate solution as blank.
Measurement of caspase-3 activity. Detection was carried out by
means of cytometry, using the Active-Caspase-3 FITC Mab apoptosis
kit (Pharmingen), according to manufacturer, which evaluates the
number of cells that contain the dimerized and activated form of
caspase-3. The range of effective measurements for this enzyme was
found to be between 14 and 48 h. Therefore, measurements were
taken at 14, 24 and 48 h, and the obtained values were compared
with those of control cells incubated without the test compounds.
The test concentrations correspond to the IC50 values determined in
the cytotoxicity assay. Cytometry was performed on a FACSCAN
(Becton Dickinson).
Measurements of central caspases activity. Caspase-3 assays were
carried out in plates of 9 cm diameter (Cellstar Greiner Bio-one).
Cells were harvested by using a 0,25% trypsin/0,03 EDTA solution
and then lysed with a buffer containing 1%Triton (100x); 50 mM
Tris HCl pH8, 150 mM NaCl, 100 µg/mL PMSF and 1mM DTT.
The soluble fraction of the cell lysate was then assayed for caspase-3
activity using Ac-DEVD-pNA, a colorimetric substrate for caspase-3.
Eighty micrograms of protein were diluted in 50 µL of caspase-3
buffer containing 50 mM HEPES pH 7,4; 100 mM NaCl, 0,1%
CHAPS, 10 mM DTT, 1 mM EDTA, 10% glycerol. Fifty micro-
liters of the substrate, DEVD-pNA (Biomol) was added to a final
concentration of 200 µM, and the plates were incubated for 24 h at
37˚C and 5% CO2. Levels of released p-nitroanitrile (pNA) were
measured as absorbance at 405 nm. To confirm the correlation
between caspase-3 activity and signal detection, control reactions
were performed by addition of 1 µL of 1 mM DEVD-CHO
(Biomol), an inhibitor of caspase-3, to the diluted protein samples
followed by addition of the reaction buffer and incubation at 37˚C
for 30 min before adding the caspase-3 substrate.6,43,44
Morphological characteristics: Caspase-3 and nuclear staining.
In order to evaluate nuclear morphology, cells were treated with the
IC50 of the compound during the time of caspase-3 activation. Cells
were washed with PBS, fixed with cold methanol at room temperature
for 15 minutes, then washed with PBS and post-fixed and perme-
abilized with methanol/acetone during 10 minutes. After blocking
with 1% BSA and 0,1% Tween 20 in PBS, 10 µg/mL of primary
antibody against caspase-3 (Sta Cruz Biotechnology) (10 µg/mL)
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were applied using anti-IgG antibody as negative control at a dilution
of 1:1000.
After overnight incubation at 4˚C overnight the antibody was
rinsed and washed with PBS (1% BSA), then treated 60 minutes
with antirabbit antibody at 1:1000 dilution (Jackson, Inmunoresearch
laboratories, INC). Further, it was washed with PBS and stained
with 4'6-diamidino-2-phenylindoline (DAPI) 1:10 dilution in PBS
and glycerol. The nuclear morphology was visualized using fluores-
cence microscopy.
Specific inhibition of caspases. To determine the involvement of
caspase-8 and caspase-9 in proapoptotic activity, a specific inhibitor
of each caspase, Z-IETD-FMK and Z-LEHD-FMK respectively and
a general caspase inhibitor (Z-VAD-fmk) were added 4 hours before
treating with JRF12; all of them were purchased from Calbiochem
(SanDiego, CA, USA). Vehicle DMSO at a final concentration of
0.5% was included as control. The effect of these inhibitors was esti-
mated by measuring cytotoxicity with neutral red assay as described
above. The experiment was performed treating cells with the caspase
inhibitors (100 µM) and 1.5 x IC50 JRF12 during 48 h, or with
25 µM of caspase inhibitors and 2 x JRF12 IC50 during 24 h.
Cell cycle analysis. Single cell suspensions were obtained from
cell monolayers as follows. First, cells were washed with PBS and
then incubated 5 minutes with trypsin. Cells were collected from the
dishes in the presence of PBS and were washed and resuspended in
1 mL of PBS. For cell cycle analysis, cells were fixed with ice-cold
100% ethanol and incubated at 4˚C for 15 minutes. Cells were then
resuspended in 125 µL of ribonuclease type IIA and incubated at
37˚C for 15 minutes, then resuspended in 125 µL of propidium
iodine (25 µg/mL) and incubated at room temperature for 30 minutes
in obscurity. Before DNA content analysis cells were filtered by
40 µm nylon mesh filter. The analysis was performed on a Becton
Dickinson FACScan flow cytometer using the CellQuest Software.
All the results were obtained from three independent experiments.
Oligonucleotide microarrays. The different cell lines were seeded
at a rate of 8 x 106 per flask, grown during 14 h and then were treated
with DMSO (vehicle control) or IC50 of JRF12 for two different
times (caspase-3 activation and DNA fragmentation). The rationale
for choosing these time points was to capture gene expression profile
of early response genes, and those involved in the induction of
apoptosis.
Total RNA from each sample was isolated using the RNeasy Midi
Kit and RNAse-free DNAse Set (QIAGEN, Valencia, CA) according
to the manufacturer’s protocols. The RNA concentration was calcu-
lated by spectrophotometry and it was adjusted to 1 µg/µL. Quality
control of RNA integrity was performed by electrophoresis on a 2%
agarose gel using ethidium bromide staining.
The 3DNA Submicro Oligo Expression Detection Kit (Genisphere)
was used to perform the reverse transcription as recommended by
manufacturer; afterwards, cDNA was prehybridized with the fluores-
cent reactive 3DNA. Then, the samples were hybridised to the slides
from the centre for Applied Genomics of the University of New Jersey.
These slides contain 18.861 oligos. After overnight hybridization at
50˚C in a slide cassette (Telechem, Sunnyvale, CA), slides were washed
sequentially in a series of solutions with increasing stringency: 2x
SSC, 0,2% SDS during 5 min at room temperature; 2x SSC 0,2%
SDS, 15 min, 42˚C; 2X SSC, during 10 min at room temperature;
and finally 0,2 × SSC during 10 min at room temperature.
To remove the systematic bias caused by the chemical difference
between Cy3 and Cy5, each microarray study was performed twice
using dye-swap.
Microarray data acquisition, normalization and analysis. The
hybridized slides were scanned with the GMS 418 scanner (Genetic
Microsystems, Woburn, MA). After image acquisition, the scanned
images were imported into “ImaGene 4.1” software (BioDiscovery)
to quantify the signal intensities. Data from spots not recognized by
the Imagene analysis software (empty, poor and negative spots) were
excluded from further considerations. We also removed data from
spots identified as visually flawed. The fluorescent median signal
intensity for each spot was calculated using local median background
subtraction. Data were normalized using Global mean, Dye-swap
Pairs normalization and Dye Swap Fix filter 1.5 with the program
ArrayNorm 1.7 (Graz, Austria).45 Log ratios above 1.7 or below -1.7
were considered as differential expression.
The data discussed in this publication have been deposited in NCBI’s
Gene Expression Omnibus (GEO, www.ncbi.nlm.nih.gov/geo/) and
are accessible through GEO Series accession number GSE3329.
Table 1 IC50 values and goodness of curve fitting (R2) of the compounds in three human tumor cell lines
T24 HT29 MDA-MB-231
Compounds IC50 (µM) R2 Compounds IC50 (µM) R2 Compounds IC50 (µM) R2
JRF3 28.95 0.9 JRF3 18.92 0.9 JRF3 4.43 0.7
JRF4 19.32 0.6 JRF4 6.96 0.9 JRF4 1.09 0.8
JRF5 5.25 0.9 JRF5 3.57 0.9 JRF5 3.13 0.9
JRF6 23.33 1.0 JRF6 5.81 0.8 JRF6 7.56 0.9
JRF7 2.86 0.7 JRF7 2.3 0.7 JRF7 2.18 0.7
JRF8 3.45 0.8 JRF8 2.2 0.9 JRF8 4.18 0.8
JRF9 11.9 0.8 JRF9 3.78 0.8 JRF9 1.22 0.7
JRF10 3.32 0.9 JRF10 3.47 0.9 JRF10 10.36 0.9
JRF11 2.17 0.9 JRF11 1.64 0.7 JRF11 4.65 0.8
JRF12 5.96 0.8 JRF12 4.72 0.9 JRF12 1.79 0.7
JRF13 15.4 0.9 JRF13 4.42 0.7 JRF13 5.47 0.7
JRF14 6.41 0.7 JRF14 5.89 0.9 JRF14 4.26 0.7
JRF15 3.87 0.8 JRF15 2.88 0.9 JRF15 3.87 0.9
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Quantitative RT-PCR. The same RNA prepared for microarray
analysis was also used for real-time RT-PCR. 2 µg of total RNA were
used to generate cDNA using the Taqman Reverse transcription
Reagent Kit (PE Applied Biosystem, Foster city, CA) according to
the manufacturer’s protocol. Each cDNA sample was analysed in
triplicate using the Abiprism7700 sequence detector (PE Applied
Biosystems). Quantitative assessment of DNA amplification was
performed using Taqman Master Mix (PE Applied biosystems). The
Q-RT-PCR reactions were carried out in a total volume of 25 µl
containing 5 µg of cDNA, 2,5 µL of the corresponding Assay on
Demand (PE Applied Biosystems), 5 µL of water and 12.5 µL of 2x
Universal PCR Master Mix. The conditions for thermal cycling
were: 2 min 50˚C, 10 min 95˚C and 40 cycles of 95˚C 15 min and
60˚C 1 min. The housekeeping gene coding for β-2 microglobuline
was used as endogenous control transcript.
Fold induction was calculated using the formula 2-∆∆Ct, were
∆Ct = target gene Ct - “housekeeping gene” Ct, and ∆∆Ct is based
on the mean of respective controls. The Ct value is determined as
the cycle at which the fluorescent signal emitted is significantly above
background levels and it is inversely proportional to the initial
template copy number.
Statistics. Data are presented as mean ± SD. IC50 values were
analysed using a non-linear regression model. Non-parametric or
parametric test were performed according to the normality test
results. The SPSS 11.0 software was used for all statistical analyses.
RESULTS
Cytotoxicity. The cytotoxic activity of the synthesized quinazoline
derivatives was determined in the three human cancer cell lines at
100 and 20 µM using the neutral red assay. All compounds were
toxic in the three cell lines tested. The IC50 values of the compounds
are shown in Table 1. We used camptothecin as reference substrate,
its IC50 values were 0.291 µM in MD-MB-231; 0,014 µM in
HT-29 and 0.006 µM in T-24.
All the compounds showed good activity against all cancer cell
lines tested, with IC50 values no higher than 30 µM.
Apoptosis detection: Caspase-3 activity and
DNA fragmentation. Once the cytotoxicity of the
compounds was verified, the induction of apoptosis
was studied. Caspase-3 is believed to serve as a general
mediator and is activated early during apoptosis. It is
often considered the key executioner apoptosis because
of its ability to cleave a vast array of proteins.5,46 The
levels of this enzyme were measured at 14, 24 and 48
h. Five compounds activate caspase-3 in T24: JRF7,
JRF8, JRF9, JRF10 and JRF12, and three in the
HT29 cell line: JRF9, JRF10 and JRF11. For MDA-
MB-231 cells the cytometry could not be performed
due to the obstruction of the cytometer by the
conglomerates these cells form in suspension.
The ability to induce DNA fragmentation in cell
culture was tested using the Cell Death detection Elisa
Plus Kit (Roche). The level of DNA degradation
measured in the control culture was considered as 1.
Five compounds showed remarkable induction of
DNA degradation in T24: JRF3, JRF5, JRF13,
JRF14 and JRF15. Six compounds induced signifi-
cant DNA degradation in HT-29: JRF4, JRF5,
JRF9, JRF12, JRF13 and JRF15. JRF5 and JRF12
showed this effect in MDA-MB-231. Only JRF5 was able to induce
DNA degradation in the three cancer cell lines while JRF12 and
JRF15 showed this effect in two cell lines.
Selectivity. In order to study the degree of selectivity, the cytotox-
icity of the compounds was tested in cell cultures of two non-tumoral
lines: CRL-8799 and CRL-11233, selected because they constitute
an in vitro model often used for pharmacotoxicological studies.47
Survival values were between 90% and 100% for JRF3, JRF4, JRF6,
JRF8 and JRF12 in CRL8799 at IC50 (Table 2).
The best values were obtained with the compounds JRF8, JRF12
and JRF15. At the highest concentration, JRF8 was not toxic in
CRL-8799 but toxic in CRL11233; inversely JRF15 was not toxic in
CRL11233, being toxic in CRL8799. The compound JRF12 was
not toxic in either cell line.
JRF12, 2,4-dibenzylaminoquinazoline (Fig. 1), was selected due
to its ability to induce at least one apoptotic event in the three tumor
cell lines tested, being not citotoxic for the non-neoplasic cell lines.
Colony formation assay. We evaluated the effects of JRF12 on
cell growth by colony formation assay. The colony number decreased
to 18 ± 0.04% and 11 ± 0.04% in T24 and HT29 cells respectively,
and a viability of 72 ± 0.02% was observed in MDA-MB-231.
There is a remarkable inhibition of cell growth both in T24 and
in HT29, but these effects are less severe in MDA-MB-231, in
which the viability decreases only a 28%.
Figure 1. The structural formula of JRF12 (2,4-dibenzylaminoquinazoline).
Table 2 Selectivity of the evaluated compounds in two non-tumoral 
cell lines
Survival values in CRL8799 Survival values in CRL11233
Compounds IC50 MDA_MB_231 Higher IC50 Higher IC50
CT 100% 0,1 100% 0,1 100% 0,1
JRF3 N.T. 0,1 0% 0,0 66% 0,6
JRF4 N.T. 0,2 4% 0,1 1% 0,0
JRF5 73% 0,0 4% 0,1 5% 0,1
JRF6 N.T. 0,0 2% 0,1 0%
JRF7 78% 0,8 11% 0,1 23% 0,2
JRF8 87% 0,0 87% 0,0 2% 0,0
JRF9 64% 0,6 6% 0,1 11% 0,2
JRF10 11% 0,1 11% 0,1 1% 0,0
JRF11 0% 0% 0,0 0%
JRF12 N.T. 89% 0,0 N.T
JRF13 70% 0,6 13% 0,1 33% 0,2
JRF14 0% 0% 0% 0,0
JRF15 0% 0% N.T
The results are shown as percentage accompanied of their respective R2.
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Time course analysis of JRF12 apoptosis induction: DNA frag-
mentation and caspase-3 activation. In T24 cells treated with the
IC50 dose of JRF12, DNA degradation began at 14 h and reached
its maximum value at 28 h. This effect did not disappear until 38 h.
The effect is slower in HT29, where it began at 24 hours reaching
its highest value at 28 hours and did not
finish until 44 hours. In the breast cell line,
MDA-MB-231, we have only found signif-
icant differences at 16 hours. This result
agrees with those found for all the com-
pounds evaluated previously that showed a
minimal effect in this cell line.
We used a colorimetric enzymatic assay
to measure changes of caspase-3 activity
between extracts prepared from control
and JRF12 treated cells. Cells were treated
with their corresponding IC50 at different
times. JRF12 stimulates caspase-3 like
activity in the three cell lines. In a time
course study, at the IC50 dose of JRF12
caspase-3 activity reached a peak after 18 h
of treatment in T24, while in HT29 this
peak appeared at 24 h and after 10 hours in
MDA-MB-231, which correlated with the
inmunofluorescence results.
The above results indicate that caspase-3-
like proteases were activated in response to
treatment with JRF12. To confirm that the
obtained signal was due to caspase-3-like
protease activity, caspase-3 inhibition by
DEVD-CHO was evaluated showing a
complete decrease of activation.6,44,48
Inmunofluorecence studies. We also
examined the activation of caspase-3 by
inmunofluorescence and the nuclear morphology of dying cells with
the fluorescent DNA-binding agent, DAPI. As shown in Figure 2,
after IC50 treatment during the time of caspase-3 activation in each
cell line, T24 cells clearly exhibited nuclear segmentation and
chromatin condensation, classical features of apoptosis, and activation
of caspase-3. No altered nuclear morphology was observed in control
cells treated with the vehicle. Thus, this result confirms that JRF12
cytotoxicity is mediated through the initiation of the apoptotic
program, corroborating the results obtained previously.
Effect of caspase inhibitors on JRF12-induced apoptosis. To
determine the involvement of caspases 8 and 9 in the cell death induced
by JRF12, and therefore the pathway the compound is activating, we
examined the effects of specific inhibitors, Z-IETD-FMK for
caspase-8 and Z-LEHD-FMK for caspase-9. We moreover examined
the effects of the general inhibitor of caspases Z-VAD-FMK on cell
viability (Fig. 3). It was evaluated at 24 and 48h.
As measured by cell viability, all the caspase inhibitors assayed
prevented induction of apoptosis after treatment with JRF12. The
general caspase inhibitor, Z-VAD-FMK, inhibits cell death in the
three cell lines evaluated, confirming that caspases are implicated in
cell death induced by JRF12. Caspase-8 and caspase-9 inhibitors also
inhibit cell death. The effect of caspase-8 is greater than that of
caspase-9 in the three cell lines tested, suggesting that JRF12 activates
cell death by caspase-8.
Cell cycle progression. Flow cytometry analysis showed that the
treatment with IC50 JRF12 for 30 h induces a progressive time-
dependent accumulation of cells in G2/M in HT29 cell line (Table 3).
G2 cell population increased from 37% in the control to 55% in the
presence of the IC50 dose of JRF12. In the mean time, cells in G1
and S phase gradually decreased; G1 percentage was 51% at time 0
and decreased to 33% at 24 hours.
Figure 2. Inmunofluorescence studies. Cells were cultured in the presence or absence of IC50 doses
JRF12 for the time of caspase-3 activation before cells were fixed, incubated with caspase-3 antibody
and stained with DAPI. Stained nuclei were then observed under fluorescent microscope. (A) Control
cells with caspase-3 antibody. (B) Control cells with DAPI. (C) Cells treated and incubated with caspase-3
antibody. (D) Cells treated and stained with DAPI.
Table 3 Effects of 2,4-dibenzylaminoquinazoline on cell 
cycle progression in HT29 and T24 cell lines
A. HT29
Sub-G1 G0/G1 S G2/M
Control 1% 51% 10% 37%
6 h 2% 43% 15% 39%
12 h 2% 45% 8% 44%
18 h 2% 37% 5% 56%
24 h 6% 33% 6% 55%
30 h 7% 39% 4% 50%
B. T24
Sub-G1 G0/G1 S G2/M
Control 6% 50% 14% 30%
6 h 8% 47% 11% 34%
12 h 9% 44% 12% 35%
18 h 24% 36% 13% 27%
24 h 26% 38% 12% 23%
30 h 35% 27% 10% 28%
Cells were treated with IC50 dose of 2,4-dibencilaminoquinazoline for different times and analyzed by flow
cytometry and the percentages of distribution of cell cycle were reported. Data are representative of three
independent experiments.
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In T24 cells (Table 3), there was a decrease in the number of cells
in G1, but not an increase in the number of cells in G2. Nevertheless,
a characteristic hypo-diploid DNA content peak (sub-G1) can be
easily detected at 24 h, time at which we have detected activation of
apoptosis previously. The slight decrease in the G2/M cell population
observed at 24 and 30 h could be explained by a decrease in the cell
G2 phase entering due to apoptosis.
Microarrays analysis. To determine whether gene expression was
affected by JRF12 treatment in the three cell lines, we used oligonu-
cleotide arrays. The different cell lines were treated with the IC50
value of JRF12 for two different times, the first corresponding to
caspase activation and the second to DNA fragmentation.
T24 cells were treated during 20 and 24 hours. At 20 h, 2 genes
were upregulated in treated cells, while 1 gene was downregulated.
At 24 h 2 genes were upregulated and 3 downregulated at the
second time (Table 4).
HT29 cells were treated for 24 and 28 hours. At 24 h, a total of
14 genes were upregulated in treated cells and 15 genes were
downregulated. At 28 h, 10 genes were upregulated and 18 down-
regulated (Table 4).
MDA-MB-231 cells were treated for 9 and 24 h. 8 genes were
upregulated while 11 were downregulated at the first of the time
points, and 7 genes were upregulated and 11 genes were downregu-
lated at the second time point (Table 4).
The limited number of genes with altered expression suggests that
JRF12 may mediate its effects via posttranscriptional mechanisms.
Microarray validation. Quantitative RT-PCR analysis was used
to confirm the results of the microarray experiments. The expression
of different genes such as ABCB8 in T24, PDCD2 and ITGAL in
MDA-MB-231 and RFP2 and ITGB4P in HT29 was evaluated
(Fig. 4). The obtained results were consistent with the microarray
data.
DISCUSSION
In this study, our aim was to find a new chemical compound able
to induce selective apoptosis in human cancer cells. We synthesized
novel symmetrical compounds based on a general pattern derived
from a nucleus of quinazoline. These compounds were tested for
cytotoxicity against three human cancer cell lines: breast
(MDA-MB-231), colon (HT-29), and bladder (T24). All the
compounds showed anticancer activity against all of the cell lines
tested, with IC50 values in the low micromolar range. Some
compounds exhibited great ability inducing apoptosis, being able to
promote caspase-3 activation and DNA degradation. Among them,
2,4-dibenzylaminoquinazoline was the compound showing better
selectivity for cancer cells, without toxicity against the non-tumoral
cell lines CRL-7899 and CRL-11233.
Figure 3. Number of viable cells 24 and 48 h after exposure to, respectively, 1,5 and 2 x IC50 doses JRF12 in presence of caspase inhibitors. (A) Cell
viability after treatment with each inhibitor in T24 for 48 h. (B) Cell viability after treatment with each inhibitor in HT29 for 48 h. (C) Cell viability after treatment
with each inhibitor in MDA-MB-231 for 48 h. (D) Cell viability after treatment with each inhibitor in T24 for 24 h. (E) Cell viability after treatment with each
inhibitor in HT29 for 24 h. (F) Cell viability after treatment with each inhibitor in MDA-MB-231 for 24 h.
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The data reported here also demonstrate
that 2,4-dibenzylaminoquinazoline is able
to induce an apoptotic response with cas-
pase-3 activation and DNA degradation in
at least two cell lines. Both events occurred
faster and earlier in T24 cells than in
HT29 cells. There is a lower induction of
apoptosis in MDA-MB-231 although cell
toxicity is present. There are several possi-
ble explanations for the discrepancies
between the sensitivity of the
MDA-MB-231 to JRF12 when measured
cell cytotoxicity and realized apoptosis
assays: the obtained results suggest that
while they appear to be less sensitive to the
apoptosis-inducing effects of 2,4-dibenzy-
laminoquinazoline, MDA-MB-231 cells
are somewhat more sensitive to this com-
pound in terms of the absolute decrease in
cell number observed in the cytotoxic
assays. This implies that additional mecha-
nisms, other than apoptosis, may work in
concert with the apoptotic program to
cause cell death in this cell line. The differ-
ences in the type of cell death induced by
2,4-dibenzylaminoquinazoline may be
linked to the diverse types of genetic alter-
ations that occur in the different tumor cell
lines.
By determination of cell cycle progression
in response to 2,4-dibenzylaminoquinazo-
line, an increase of G2 /M arrest was
detected in HT29, while in T24 we
observed cell death instead of cell cycle
arrest. Our study shows that HT29 cells
exposed to the IC50 dose of 2,4-dibencil-
aminoquinazoline undergo prolonged but
transient G2/M arrest followed by G2 to M
progression and after that cell death or G1
progression. Whereas T24 cells exposed to
IC50 dose of 2,4-dibencilaminoquinazo-
line undergo decreased G1 population fol-
lowed by S to G2 transit and apoptotic cell
death.
Our data indicate that 2,4-dibenzy-
laminoquinazoline induced cell cycle arrest
in G2 and apoptosis may result from the
activation of the same signal transduction
pathways, because G2 arrest seems to be
followed in both cell lines by apoptosis
activation, although this effect is slower in
HT29.
To further define the mechanism by
which JRF12 promotes the apoptotic
pathway, the effect of caspase inhibition
was evaluated. In all the cell lines tested the
caspase inhibitors partially inhibit cell
death. Caspase-8 inhibition was greater
than caspase-9 indicating that JRF12 cell
death is mainly activated by caspase-8.
Table 4 Genes upregulated and down-regulated in the three cancer 
cell lines exposed to the IC50 of JRF12 at two times
A. HT29
Genebank Symbol Description
Caspase-3 activation
Upregulated
AK025684 Homo sapiens cDNA: FLJ22031 fis, clone HEP08734
NM_018246 Homo sapiens hypothetical protein FLJ10853 (FLJ10853),
AF164963 Homo sapiens tumor antigen NA88-A pseudogene, complete sequence
NM_018026 PACS1 Homo sapiens phosphofurin acidic cluster sorting protein 1
Z36816 H.sapiens (xs164) mRNA, 400bp
AF147368 Homo sapiens full length insert cDNA clone YB64D10
AJ224170 Homo sapiens mRNA containing U19H snoRNA
NM_012244 SLC7A8 Homo sapiens solute carrier family 7
U61095 Human NTera2D1 cell line mRNA containing L1 retroposon, clone P6
NM_001433 Homo sapiens ER to nucleus signalling 1
AB007859 Homo sapiens mRNA for KIAA0399 protein
AJ243673 Homo sapiens cDNA from NICE-2 gene
NM_016385 CYLD Homo sapiens cylindromatosis
Downregulated
D17207 Human HepG2 3' region MboI cDNA, clone hmd3e08m3
AK026753 Homo sapiens cDNA: FLJ23100 fis, clone LNG07523
NM_005798 RFP2 Homo sapiens ret finger protein 2
AF131781 Homo sapiens clone 24901 mRNA sequence, complete cds
AL109684 Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 27080.
NM_015485 RWDD3 Homo sapiens RWD domain containing 3
NM_013275 Homo sapiens cDNA FLJ11564 fis, clone HEMBA1003220
AK023929 Homo sapiens cDNA FLJ13867 fis, clone THYRO1001262
AF086501 Homo sapiens full length insert cDNA clone ZE01F07.
AK026942 Homo sapiens cDNA: FLJ23289 fis, clone HEP10028
NM_003436 ZNF135 Homo sapiens zinc finger protein 135
NM_006733 FSHPRH1 Homo sapiens FSH primary response
NM_013339 ALG6 Homo sapiens asparagine-linked glycosylation 6 homolog
U12028 Human Cri-du-chat mRNA, partial sequence
AK021778 Homo sapiens cDNA FLJ11716 fis, clone HEMBA1005232
NM_001036 RYR3 Homo sapiens ryanodine receptor 3
DNA degradation
Upregulated
AK026984 Homo sapiens cDNA: FLJ23331 fis, clone HEP12664
AK022471 Homo sapiens cDNA FLJ12409 fis, clone MAMMA1002895
NM_000212 ITGB3 Homo sapiens integrin, beta 3
AB024518 Homo sapiens mRNA for DVS27-related protein, complete cds
NM_003522 HIST1H2BF Homo sapiens histone 1, H2bf
AK021626 Homo sapiens cDNA FLJ11564 fis, clone HEMBA1003220
AF086176 Homo sapiens cDNA FLJ13867 fis, clone THYRO1001262
NM_015972 POLR1D Homo sapiens polymerase (RNA) I polypeptide D, 16kDa
U50537 Human BRCA2 region, mRNA sequence CG033
AK022856 Homo sapiens cDNA FLJ12794 fis, clone NT2RP2002041
Downregulated
M73837 MRF-2 Homo sapiens modulator recognition factor 2
NM_002212 ITGB4BP Homo sapiens integrin beta 4 binding protein
AB037804 Homo sapiens mRNA for KIAA1383 protein
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In the apoptotic cascade, caspase-8 is
the most upstream enzyme mediating
death receptor apoptosis pathways, and its
activation propagates the apoptotic signal
by activating executioner caspases such as
caspase-3. Caspase-8, in addition to activa-
tion of caspase-3, has the ability to cleave
BH3 interacting domain death agonist
(Bid). The truncated Bid interacts with the
proapoptotic protein Bax, inducing a
conformational change of Bax that promotes
the release of cytochrome c from mito-
chondria to cytosol, therefore activating
caspase-9, which activates executioner
caspases.49
Our preliminary studies using microarray
analysis to assess the effects of 2,4-diben-
cilaminoquinazoline on gene expression
found no genes whose expression was
altered in the three cell lines at both of the
times examined.
Because of the few genes with differential
expression we consider that 2,4-dibenzy-
laminoquinazoline mediate its effect via
posttranscriptional changes.
In summary, our results show that
2,4-dibenzylaminoquinazoline stimulates
activation of caspase-3 activity and DNA
degradation in cancer cell lines, resulting
in significant cell death upon continuous
treatment with the drug.
Regarding the molecular mechanism of
action of 2,4-dibenzylaminoquinazoline, it
has been shown that quinazoline derivatives
have the ability to inhibit tyrosine kinase
activity, being able to interfere with different
intracellular signal transduction pathways.50
For instance, several quinazoline derivatives
inhibit the ErbB family of tyrosine kinase
proteins. When these receptors are activated,
dimerization is followed by activation of
intrinsic protein tyrosine kinase activity,
tyrosine phosphorylation, and activation
of intracellular signal transduction path-
ways, such as the phosphathidylinositol
3-kinase (PI3K)/ AKT and the ras/raf/
MEK/MAPK pathways.51
Several quinazoline derivatives may also
activate the intracellular effect of the
integrin pathway, activating kinases such
as FAK and PKB/Akt, that are critical
elements of anchorage-mediated survival
signaling.52 These signal transduction
pathways finally act phosphorilating, and
thereby activating, different proteins related
to apoptosis like, for example, MAP
phosphorilation of BAD.33 Recently, it has
been shown that these quinazolines
derivatives, such as doxazosin, also activate
Table 4 Genes upregulated and down-regulated in the three cancer 
cell lines exposed to the IC50 of JRF12 at two times (continued)
A. HT29 (continued)
Genebank Symbol Description
DNA Degradation
Downregulated
AL442116 Novel human gene mapping to chomosome 22
AJ002785 Homo sapiens mRNA; Clontech fetal brain cDNA JAGF6 5
NM_016153 LW-1 Homo sapiens LW-1
AK025616 Homo sapiens cDNA: FLJ21963 fis, clone HEP05583
NM_017984 Homo sapiens zinc finger, CW-type with PWWP domain 1
NM_006478 GAS2L1 Homo sapiens growth arrest-specific 2 like 1
AL117617 Homo sapiens mRNA; cDNA DKFZp564H0764
AL079292 Homo sapiens mRNA full length insert cDNA clone EUROIMAGE 48814
AK025234 Homo sapiens cDNA: FLJ21581 fis, clone COL06796
NM_016073 HDGFRP3 Homo sapiens hepatoma-derived growth factor, related protein 3
AK022660 Homo sapiens cDNA FLJ12598 fis, clone NT2RM4001384
NM_003816 ADAM9 Homo sapiens a disintegrin and metalloproteinase domain 9
NM_004967 IBSP Homo sapiens integrin-binding sialoprotein
AF014459 XLRS1 Homo sapiens X-linked juvenile retinoschisis precursor protein
AK022956 Homo sapiens cDNA FLJ12894 fis, clone NT2RP2004170
B. T24
Genebank Symbol Description
Caspase-3 activation
Upregulated
L38282 Homo sapiens 30a mRNA fragment
NM_007188 ABCB8 Homo sapiens ATP-binding cassette, sub-family B
Downregulated
AF236158 HT021 Homo sapiens HT021
NM_000414 HSD17B4 Homo sapiens hydroxysteroid (17-beta) dehydrogenase 4
DNA Degradation
Upregulated
Z83935 H.sapiens mRNA; clone CD 43T3
Downregulated
AK026322 Homo sapiens cDNA: FLJ22669 fis, clone HSI08594
NM_018250 FLJ10871 Homo sapiens hypothetical protein FLJ10871
AK021869 Homo sapiens cDNA FLJ11807 fis, clone HEMBA1006284
C. MDA-MB-231
Genebank Symbol Description
Caspase-3 activation
Upregulated
NM_005053 RAD23A Homo sapiens RAD23 homolog A (S. cerevisiae)
NM_014440 IL1F6 Homo sapiens interleukin 1 family, member 6
NM_000366 TPM1 Homo sapiens tropomyosin 1 (alpha)
NM_002598 PDCD2 Homo sapiens programmed cell death 2
NM_001756 SERPINA6 Homo sapiens serine (or cysteine) proteinase inhibitor
AB028947 Homo sapiens mRNA for KIAA1024 protein
NM_004258 IGSF2 Homo sapiens immunoglobulin superfamily, member 2
Downregulated
AK026734 Homo sapiens cDNA: FLJ23081 fis, clone LNG06331
AK026413 Homo sapiens cDNA: FLJ22760 fis, clone KAIA0881.
NM_007352 ELA3B Homo sapiens elastase 3B, pancreatic
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the extrinsic pathway of apoptosis activating caspase-8 in a Fas ligand
independent way.53
For all this reasons we suggest that 2,4-dibencilaminoquinazoline
may act inhibiting some tyrosine kinase like other quinazoline deriv-
atives, altering intracellular signal transduction pathways and
indirectly activating apoptosis.
Finally, these results suggest that 2,4-dibencilaminoquinazoline may
be attractive as a novel investigational drug, although further studies
are required to detail the mechanism of action, animal models of
different neoplasms may be useful to characterize the preclinical
profile of this apoptosis inducer drug.
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Figure 4. Gene expression analysis of tumoral cells treated with 2,4-diben-
cilaminoquinazoline by real-time quantitative RT-PCR. (A) HT29, (B) T24 and
(C) MDA-MB-231.
